Cronos GroupSTU:7CI -0.99%84 Return-on-Tangible-Equity is 5.49% as of Mar. 2026. GuruFocus rates STU:7CI with a GF Score™ of 84/100 and a GF Value™ of €3.09 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 897 Drug Manufacturers companies, Cronos Group ranks worse than 71.24% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Cronos Group's annualized net income for the quarter that ended in Mar. 2026 was €47.6 Mil. Cronos Group's average shareholder tangible equity for the quarter that ended in Mar. 2026 was €867.3 Mil. Therefore, Cronos Group's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 5.49%.
The historical rank and industry rank for Cronos Group's Return-on-Tangible-Equity or its related term are showing as below:
STU:7CI'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -28.48 Med: -5.82 Max: 145.28
Current: -0.14
During the past 12 years, Cronos Group's highest Return-on-Tangible-Equity was 145.28%. The lowest was -28.48%. And the median was -5.82%.
STU:7CI's Return-on-Tangible-Equity is ranked worse than 71.24% of 897
companies
in the Drug Manufacturers industry
Industry Median: 7.9
vs STU:7CI: -0.14
Cronos Group (STU:7CI) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Cronos Group Return-on-Tangible-Equity Related Terms
Cronos Group Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Cronos Group's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:7CI vs ZTS, UTHR: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Cronos Group's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cronos Group Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cronos Group's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Cronos Group's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 5.49% mean?
Cronos Group (STU:7CI) has a Return-on-Tangible-Equity of 5.49% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Cronos Group and its competitors. According to the industry distribution chart, Cronos Group ranks #639 out of 897 companies in the Drug Manufacturers industry, placing it in the top 71.2%.
Is Cronos Group's Return-on-Tangible-Equity too high?
Cronos Group's current Return-on-Tangible-Equity is 5.49%. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. Cronos Group's value of 5.49% is 30.5% below this industry median. Based on the distribution chart, Cronos Group ranks #639 out of 897 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Cronos Group has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cronos Group's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cronos Group ranks #639 out of 897 companies for Return-on-Tangible-Equity. This places Cronos Group in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.90. Cronos Group's value of 5.49% is 30.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 897 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cronos Group's current Return-on-Tangible-Equity of 5.49% is 30.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Cronos Group and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cronos Group's current Return-on-Tangible-Equity is 5.49%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cronos Group stock overvalued right now?
Based on GuruFocus' analysis, Cronos Group (STU:7CI) is currently considered Modestly Undervalued. The stock's GF Value™ is €3.09, compared to a current price of €2.40 — trading 22.2% below its estimated fair value. The current Return-on-Tangible-Equity is 5.49% and 30.5% below the Drug Manufacturers industry median of 7.90. Cronos Group's overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Cronos Group (STU:7CI), the current Return-on-Tangible-Equity is 5.49% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cronos Group (STU:7CI) Overvalued in 2026?
Based on GuruFocus' analysis, Cronos Group stock appears to be undervalued.
The current stock price of €2.40 is trading 22.2% below its estimated GF Value™ of €3.09.
GuruFocus considers Cronos Group to be Modestly Undervalued.
Key valuation signals for STU:7CI:
Return-on-Tangible-Equity: 5.49%
GF Value™: €3.09 vs. price of €2.40 (22.2% below fair value)
Industry Position: 30.5% below the Drug Manufacturers median (#639 of 897)
No single metric tells the full story. See the STU:7CI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cronos Group Inc is a cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology, and product development. With a passion for responsibly elevating the consumer experience, the company is building an iconic brand portfolio. Its diverse international brand portfolio includes Spinach, PEACE NATURALS, LIT, and Lord Jones. The company operates in Canada, Israel, and other countries, with the majority of its revenue generated from Canada.
84GF Score
Get the complete analysis for STU:7CI
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:7CI has been successfully added to your 
